Cargando…

Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study

AIM: To assess the potential gain in the number of life‐years free of a (recurrent) cardiovascular disease (CVD) event with optimal cardiovascular risk management (CVRM) and initiation of glucose‐lowering agents with proven cardiovascular benefit in people with type 2 diabetes (T2D). MATERIALS AND M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Østergaard, Helena Bleken, Humphreys, Valerie, Hengeveld, Ellen Margo, Honoré, Julie Broe, Mach, François, Visseren, Frank L. J., Westerink, Jan, Yadav, Gourav, Mosenzon, Ofri
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092227/ https://www.ncbi.nlm.nih.gov/pubmed/36199242 http://dx.doi.org/10.1111/dom.14887

Ejemplares similares

Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. Diabetes Care 2021;44:901–907
por: Østergaard, Helena Bleken, et al.
Publicado: (2021)

Lifestyle changes and kidney function: A 10‐year follow‐up study in patients with manifest cardiovascular disease
por: Østergaard, Helena Bleken, et al.
Publicado: (2022)

End-stage kidney disease in patients with clinically manifest vascular disease; incidence and risk factors: results from the UCC-SMART cohort study
por: Østergaard, Helena Bleken, et al.
Publicado: (2021)

Efficacy of liraglutide added to sodium‐glucose cotransporter‐2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post‐hoc analysis of LIRA‐ADD2SGLT2i
por: Blonde, Lawrence, et al.
Publicado: (2021)

Intensification of Insulin Therapy for Type 2 Diabetic Patients in Primary Care: Basal-Bolus Regimen Versus Premix Insulin Analogs: When and for whom?
por: Mosenzon, Ofri, et al.
Publicado: (2013)

Early Insulinization to Prevent Diabetes Progression
por: Raz, Itamar, et al.
Publicado: (2013)

Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs
por: Cherney, David Z.I., et al.
Publicado: (2022)

Paving the way to precision medicine for diabetic kidney disease: the PRIORITY trial
por: Schechter, Meir, et al.
Publicado: (2020)

Preventing all‐cause hospitalizations in type 2 diabetes with sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A narrative review and proposed clinical approach
por: Schechter, Meir, et al.
Publicado: (2022)

Muon lifetime and muon capture
por: Lauss, B
Publicado: (2004)

Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial
por: Persson, Frederik, et al.
Publicado: (2021)

Pharmacological and non-pharmacological interventions to influence adipose tissue function
por: Westerink, Jan, et al.
Publicado: (2011)

Prediction of Lifetime and 10-Year Risk of Cancer in Individual Patients With Established Cardiovascular Disease
por: van ’t Klooster, Cilie C., et al.
Publicado: (2020)

Lifetime benefits of musical training
por: Paquette, Sébastien, et al.
Publicado: (2014)

Diabetes and Stroke: What Are the Connections?
por: Mosenzon, Ofri, et al.
Publicado: (2023)

Lifetime benefits of early detection and treatment of diabetic kidney disease
por: Thornton Snider, Julia, et al.
Publicado: (2019)

Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective?
por: Berkelmans, Gijs F. N., et al.
Publicado: (2020)

Abstract 25: Glycemic variability of oral semaglutide versus empagliflozin: A post hoc analysis of PIONEER 2
por: Shabeer, D, et al.
Publicado: (2022)

Impact of a Patient’s Baseline Risk on the Relative Benefit and Harm of a Preventive Treatment Strategy: Applying Trial Results in Clinical Decision Making
por: de Vries, Tamar I., et al.
Publicado: (2021)

Estimating the Lifetime Benefits of Treatments for Heart Failure
por: Ferreira, João Pedro, et al.
Publicado: (2020)

Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials
por: Mosenzon, Ofri, et al.
Publicado: (2022)

Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
por: Waijer, Simke W., et al.
Publicado: (2022)

What is important for people with type 2 diabetes? A focus group study to identify relevant aspects for Patient-Reported Outcome Measures in diabetes care
por: Abdel-Rahman, Nura, et al.
Publicado: (2022)

Redundant laboratory testing on referral from general practice to the outpatient clinic: a post-hoc analysis
por: Vrijsen, Bram EL, et al.
Publicado: (2021)

CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries
por: Mosenzon, Ofri, et al.
Publicado: (2021)

A novel measurement of the muon capture rate in liquid hydrogen by the lifetime technique
por: Bardin, G, et al.
Publicado: (1980)

Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program
por: Lingvay, Ildiko, et al.
Publicado: (2023)

Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence
por: Schechter, Meir, et al.
Publicado: (2021)

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial
por: Mosenzon, Ofri, et al.
Publicado: (2022)

From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Dynamic Cooperative Clustering Based Power Assignment: Network Capacity and Lifetime Efficient Topology Control in Cooperative Ad Hoc Networks
por: Li, Xiao-Hong, et al.
Publicado: (2014)

Statement on bioinformatics and capturing the benefits of genome sequencing for society
por: Capps, Benjamin, et al.
Publicado: (2019)

Arterial stiffness as a risk factor for cardiovascular events and all‐cause mortality in people with Type 2 diabetes
por: Sharif, S., et al.
Publicado: (2019)

Fast‐acting insulin aspart versus insulin aspart in the setting of insulin degludec‐treated type 1 diabetes: Efficacy and safety from a randomized double‐blind trial
por: Buse, John B., et al.
Publicado: (2018)

Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers
por: Tye, Sok Cin, et al.
Publicado: (2022)

Conditioned media from (pre)adipocytes stimulate fibrinogen and PAI-1 production by HepG2 hepatoma cells
por: Faber, D R, et al.
Publicado: (2012)

Proposal for Post Hoc Quality Control in Instrumented Motion Analysis Using Markerless Motion Capture: Development and Usability Study
por: Röhling, Hanna Marie, et al.
Publicado: (2022)

Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial
por: Mann, Johannes F. E., et al.
Publicado: (2018)

OR22-1 Liraglutide as Add-on to SGLT2 Inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double-Blind, Placebo-Controlled Trial
por: Blonde, Lawrence, et al.
Publicado: (2019)

Oral Semaglutide Reduces HbA(1c) and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses
por: Pratley, Richard E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l5n80ogfpmscuk7ck4e32krkd1